Andira Medicine Inc. has filed an amendment to its previous offering, revealing a total offering amount of $220,000. This update is significant as it underscores the company's ongoing efforts to secure funding for its operations and potential expansion.

Andira Medicine Inc. is a corporation incorporated in British Columbia, Canada. The company has been active in the biotechnology sector and is focused on innovative solutions. Their recent filings indicate a commitment to raising capital through private offerings.

The latest filing, dated November 6, 2026, indicates that the company has successfully sold the entire offering amount of $220,000. The filing states, "totalAmountSold: 220000" and confirms that there are no remaining funds available from this offering.

This amendment may affect various stakeholders, including the company's directors and executive officers, such as Dana Lambert, Ethan Russo, Michael Stuart Wall, Ammad Shorbaji, and Janette Lyons, all of whom are based in North Vancouver, British Columbia.

The filing does not specify what happens next for Andira Medicine Inc. However, the completion of this offering may provide the necessary capital for future projects or initiatives.

Details of the Offering

The offering was structured under Rule 506(b), which provides a safe harbor for private offerings, allowing Andira Medicine Inc. to raise funds while remaining compliant with SEC regulations. The total amount sold was $220,000, with no remaining funds available from this offering.

According to the filing, the offering included various types of securities, such as equity, debt, and options to acquire. The company did not accept minimum investments, allowing for broader participation from investors.

Sales Compensation and Fees

Andira Medicine Inc. incurred sales commissions totaling $13,200 as part of the offering, with no finders' fees reported. Additionally, the company has issued 3% five-year common share warrants as part of the compensation structure.

Investor Participation

The filing indicates that there were two investors involved in this offering, and notably, there were no non-accredited investors. This suggests that the company targeted accredited investors for this fundraising effort.

Use of Proceeds

While the filing does not specify how the proceeds from the offering will be utilized, it notes that no gross proceeds have been used to date. This could imply that the funds are earmarked for future projects or operational costs, though specific allocations remain undisclosed.

Company Background and Operations

Andira Medicine Inc. is incorporated in British Columbia, Canada, and has been in operation for over five years. The company is engaged in the biotechnology sector, focusing on innovative solutions, although specific details about its projects or research initiatives are not provided in the filing.

Furthermore, the filing does not include any information regarding the company's financial performance, future business plans, or potential risks associated with its operations. These aspects could be critical for stakeholders and investors looking to understand the company's trajectory.